Navigation Links
ShangPharma Corporation to Announce First Quarter 2011 Financial Results on May 19, 2011

SHANGHAI, May 9, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the first quarter 2011 ended March 31, 2011 on May 19, 2011. Management will host a conference call to discuss the results at 8:00am New York Time on May 19, 2011 (8:00pm Beijing time on May 19, 2011).

Conference Call Mr. Michael Hui, founder and Chief Executive Officer, Mr. Kevin Chen, President and Chief Operating Officer, and Mr. William Dai, Chief Financial Officer, will discuss the results and take questions following the prepared remarks.

The dial-in details for the live conference call are as follows:- U.S. Toll Free Number:  

1.888.396.2369- International dial-in number:1.617.847.8710- China Toll Free Number:

10 800 152 1490 (North)10 800 852 1490 (South)- Hong Kong Toll Free Number:

800 96 3844Passcode:

SHPA live webcast of the conference call will be available on the investor relations section of the Company's website at:

A telephone replay of the call will be available for seven days from May 19, 2011 to May 26, 2011. The dial-in details for the replay are as follows: - U.S. Toll Free Number:

1-888-286-8010- International dial-in number:1-617-801-6888Passcode:

64510327About ShangPharma Corp.ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit

For further information, contact:ShangPharma CorporationLan Xie, VP of Finance and OperationsE-mail: IR@shangpharma.comChristensenIn New YorkKimberly Minarovich,Phone: +1 917-533-3268E-mail: kminarovich@christensenir.comIn Hong KongTip FlemingPhone: +852-9212-0684Email:  

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma Announces Appointment of Benson Tsang as a Member of the Board of Directors and Audit Committee
2. ShangPharma to Present at the Citibank Global Health Care Conference from March 1 - 3, 2011
3. ShangPharma Announces Fourth Quarter and Fiscal Year 2010 Results
4. ShangPharma Corporation Files 2010 Annual Report on Form 20-F
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. CEL-SCI Corporation Releases Letter to Shareholders
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
9. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
10. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
11. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... On November 25, 2015, officials of Narconon Arrowhead ... the release of a new cutting edge recovery program that has been 50 years ... drug- and alcohol-addicted individuals with the purpose to free addicts from the symptoms and ...
(Date:11/25/2015)... ... ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David Adcock ... , According to court documents, Adcock testified that on May 10, 2010 he sat ...
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is pleased to ... facial wrinkling. While many patients are aware of the benefits of Botox® in the ... to those suffering with discomfort, soreness, and pain as a result of Jaw Tension, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... , ... November 25, 2015 , ... In an ongoing ... Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its ... surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 at ...
Breaking Medicine News(10 mins):